Cardiff Oncology Inc

CRDF remains in Stage 4 decline with medium-term bearish bias—execution should focus on trimming into rallies around the declining 9/21 EMA zone and prior consolidation highs. Short-term timing is neutral amid extreme oversold conditions, suggesting deferred engagement until relief bounces stall.

• ↑Onvansertib shows 64% ORR in 30 mg cohort vs 33% in control arm.
• ↑Strategic shift to first-line RAS-mutated mCRC backed by FDA guidance.
• ↓Q4 cash burn of ~$10.3M per quarter strains the $91.7M runway.